Brokerages Set Astera Labs, Inc. (NASDAQ:ALAB) Target Price at $152.94

Key Points

• Astera Labs, Inc. has received a consensus rating of "Moderate Buy" from analysts, with 15 buy recommendations, 3 holds, and 1 strong buy out of 19 ratings firms.
• The average 12-month price target for Astera Labs is approximately $152.94, with significant updates from various analysts raising their targets recently.
• In its latest earnings report, Astera Labs reported $191.93 million in revenue and an EPS of $0.44, exceeding consensus estimates and marking a 149.5% increase in revenue year-over-year.

Astera Labs, Inc. (NASDAQ:ALAB - Get Free Report) has received an average rating of "Moderate Buy" from the nineteen analysts that are covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, fifteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $152.9375.

Several brokerages have weighed in on ALAB. Wall Street Zen raised shares of Astera Labs from a "hold" rating to a "buy" rating in a report on Saturday, August 16th. Northland Securities cut shares of Astera Labs from an "outperform" rating to a "market perform" rating and set a $120.00 price objective on the stock. in a research report on Tuesday, July 22nd. Morgan Stanley lifted their price objective on shares of Astera Labs from $155.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday, August 29th. Susquehanna lifted their price objective on shares of Astera Labs from $80.00 to $125.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Finally, Zacks Research upgraded shares of Astera Labs to a "strong-buy" rating in a research report on Tuesday, August 12th.

Insider Activity

In other news, General Counsel Philip Mazzara sold 10,000 shares of Astera Labs stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $188.70, for a total transaction of $1,887,000.00. Following the sale, the general counsel owned 161,573 shares in the company, valued at $30,488,825.10. This trade represents a 5.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Sanjay Gajendra sold 91,441 shares of the business's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $183.51, for a total transaction of $16,780,337.91. Following the completion of the sale, the chief operating officer owned 2,170,877 shares in the company, valued at $398,377,638.27. This represents a 4.04% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,576,713 shares of company stock valued at $239,237,016. Company insiders own 12.50% of the company's stock.

Institutional Investors Weigh In On Astera Labs

Large investors have recently bought and sold shares of the business. Oliver Lagore Vanvalin Investment Group bought a new stake in Astera Labs in the second quarter worth $29,000. Bernard Wealth Management Corp. bought a new stake in Astera Labs in the second quarter worth $36,000. Clearstead Trust LLC increased its position in Astera Labs by 46,100.0% in the second quarter. Clearstead Trust LLC now owns 462 shares of the company's stock worth $42,000 after purchasing an additional 461 shares during the last quarter. Advisors Asset Management Inc. increased its position in Astera Labs by 68.6% in the second quarter. Advisors Asset Management Inc. now owns 477 shares of the company's stock worth $43,000 after purchasing an additional 194 shares during the last quarter. Finally, Manchester Capital Management LLC increased its position in Astera Labs by 141.5% in the second quarter. Manchester Capital Management LLC now owns 483 shares of the company's stock worth $44,000 after purchasing an additional 283 shares during the last quarter. Institutional investors own 60.47% of the company's stock.

Astera Labs Stock Down 3.2%

NASDAQ:ALAB traded down $7.90 during trading hours on Monday, hitting $237.30. 6,356,998 shares of the stock traded hands, compared to its average volume of 5,539,283. Astera Labs has a 1 year low of $47.13 and a 1 year high of $262.90. The company has a market cap of $39.44 billion, a price-to-earnings ratio of 462.64, a price-to-earnings-growth ratio of 6.22 and a beta of 1.46. The stock has a 50 day moving average price of $169.95 and a 200 day moving average price of $110.12.

Astera Labs (NASDAQ:ALAB - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.11. Astera Labs had a net margin of 16.54% and a return on equity of 9.53%. The business had revenue of $191.93 million for the quarter, compared to the consensus estimate of $172.46 million. During the same quarter in the previous year, the firm earned $0.13 earnings per share. The company's revenue for the quarter was up 149.5% on a year-over-year basis. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. Equities analysts forecast that Astera Labs will post 0.34 earnings per share for the current fiscal year.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.